This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DON
Seeking Income? Consider These 3 Dividend Aristocrats
by Derek Lewis
During times of heightened volatility, an established income stream is undoubtedly a major positive, allowing investors to offset losses in other positions and reap those sweet dividend payouts.
Cardinal Health (CAH) Lowers Medical Segment Income Guidance
by Zacks Equity Research
Cardinal Health (CAH) projects Medical segment loss to be in the range of $25 million to $55 million for the first quarter of fiscal 2023, owing to inventory charges related to the company's gloves portfolio.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
Company News for Aug 16, 2022
by Zacks Equity Research
Companies In The News Are: DIS, CAH, U, APP, TSLA.
Cardinal Health (CAH) Q4 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results benefit from a solid performance in the Pharmaceutical segment.
Cardinal Health (CAH) Lags Q4 Earnings Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of -10.26% and 5.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 68% and 1.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Invacare (IVC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of -20.45% and 11.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.
Cardinal Health (CAH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health's (CAH) New Buyout to Boost Medication Adherence
by Zacks Equity Research
Cardinal Health's (CAH) latest acquisition is expected to significantly improve patients' health outcomes with improved medication adherence and increased satisfaction.
New Strong Sell Stocks for July 8th
by Zacks Equity Research
ACER, CAH, and DRI have been added to the Zacks Rank #5 (Strong Sell) List on July 8, 2022.
Cardinal Health (CAH) Buys Bendcare CPO-GPO, Invests in Its MSO
by Zacks Equity Research
Cardinal Health's (CAH) latest acquisition is expected to significantly boost its distribution opportunities and improve patient service.
Cardinal Health (CAH) Ties Up to Deliver Products Via Drones
by Zacks Equity Research
Cardinal Health's (CAH) latest collaboration is expected to significantly boost its distribution strategy and improve patient service.
New Strong Sell Stocks for June 27th
by Zacks Equity Research
CNMD, WMT, and CAH have been added to the Zacks Rank #5 (Strong Sell) List on June 27, 2022.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Cardinal Health (CAH) to Extend Warehouse Footing With New Center
by Zacks Equity Research
Cardinal Health's (CAH) new distribution center to support the company's at-Home Solutions business.
Cardinal Health (CAH) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results benefit from a solid performance in the Pharmaceutical segment.
Cardinal Health (CAH) Q3 Earnings Miss Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of -5.84% and 4.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stocks' Earnings May 5 Roster: MCK, CAH & PODD
by Debanjana Dey
The Medical Product companies' quarterly results are likely to reflect base business recovery. Let's see how MCK, CAH and PODD are poised ahead of their earnings releases.
AmerisourceBergen (ABC) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AmerisourceBergen (ABC) delivered earnings and revenue surprises of 7.69% and 0.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
Cardinal Health (CAH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) Stock Moves -1%: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $60.63 in the latest trading session, marking a -1% move from the prior day.